Cancer research software provider Owkin received the funding as part of a strategic collaboration partnership which will involve it working with Sanofi on potential treatments.
Pharmaceutical firm Sanofi provided $180m in equity funding yesterday for Owkin, the US-headquartered developer of a software platform that enables researchers to collaborate on cancer drug development.
Owkin’s software utilises federated learning and collaborative artificial intelligence technology to help cancer researchers and hospitals share siloed data without compromising the privacy of patients.
The Sanofi investment was made through a strategic collaboration agreement which will involve it supplying $90m over three years to support discovery and development work on four kinds…
